EPISODE · Oct 13, 2025 · 1H 7M
Daniela Marino, CUTISS 🇨🇭 | Tissue Engineering, Skin Grafts | E42 [Sponsored]
from Flot.bio x Philip Hemme · host Flot.bio
Hot on the heels of CUTISS’ $60M Series C round, we catch up once more with CEO and co-founder Daniela Marino. We chat about the company’s mission to develop an engineered tissue therapy to reduce the need for skin grafts in patients with severe burns. She also explains the decentralization of tissue manufacturing with automation and the need for perseverance as a founder and CEO.---This episode is sponsored by CUTISS, the only TechBio company in the advanced clinical stage of developing skin tissue therapies. Learn how you can support CUTISS on its path to Series C success: https://bit.ly/flotbio-cutiss---⭐️ ABOUT THE SPEAKERIn 2023, Daniela Marino was named as one of the 30 Rising Leaders in the healthcare industry, thanks to the impact of CUTISS, the company she co-founded as a spin-off from the University of Zurich. Here, she and her team have made waves for people suffering from severe skin injuries and defects through regenerative medicine, tissue engineering, and skin pigmentation.🔗 LINKS MENTIONED- CUTISS’ website – https://cutiss.swiss/- CUTISS’ Series C round – https://cutiss.swiss/cutiss-closes-chf-56m-series-c-round-and-signs-agreement-with-leading-european-burn-center/- CUTISS’ Phase II trial data – https://cutiss.swiss/phase-2-clinical-trials-update-from-cutiss/- Daniela Marino, CUTISS 🇨🇭 | Skin Tissue Therapeutics, TechBio | E33 – https://flot.bio/episode/daniela-marino-cutiss-skin-tissue-therapeutics/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/daniela-marino-cutiss-tissue-engineering/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro- [00:02:31] Investors in CUTISS’ Series C round [00:06:45] Expanding a hospital collaboration [00:08:34] Decentralized manufacturing drive [00:11:50] Tissue therapeutics vs skin grafts [00:24:35] Reimbursement and health economics [00:38:39] CUTISS’ partnering and exit options [00:47:54] Automation and artificial intelligence [00:56:32] Europe can show its strength in biotech [00:58:52] Daniela Marino answers quick-fire questions
What this episode covers
Hot on the heels of CUTISS’ $60M Series C round, we catch up once more with CEO and co-founder Daniela Marino. We chat about the company’s mission to develop an engineered tissue therapy to reduce the need for skin grafts in patients with severe burns. She also explains the decentralization of tissue manufacturing with automation and the need for perseverance as a founder and CEO.---This episode is sponsored by CUTISS, the only TechBio company in the advanced clinical stage of developing skin tissue therapies. Learn how you can support CUTISS on its path to Series C success: https://bit.ly/flotbio-cutiss---⭐️ ABOUT THE SPEAKERIn 2023, Daniela Marino was named as one of the 30 Rising Leaders in the healthcare industry, thanks to the impact of CUTISS, the company she co-founded as a spin-off from the University of Zurich. Here, she and her team have made waves for people suffering from severe skin injuries and defects through regenerative medicine, tissue engineering, and skin pigmentation.🔗 LINKS MENTIONED- CUTISS’ website – https://cutiss.swiss/- CUTISS’ Series C round – https://cutiss.swiss/cutiss-closes-chf-56m-series-c-round-and-signs-agreement-with-leading-european-burn-center/- CUTISS’ Phase II trial data – https://cutiss.swiss/phase-2-clinical-trials-update-from-cutiss/- Daniela Marino, CUTISS 🇨🇭 | Skin Tissue Therapeutics, TechBio | E33 – https://flot.bio/episode/daniela-marino-cutiss-skin-tissue-therapeutics/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/daniela-marino-cutiss-tissue-engineering/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro- [00:02:31] Investors in CUTISS’ Series C round [00:06:45] Expanding a hospital collaboration [00:08:34] Decentralized manufacturing drive [00:11:50] Tissue therapeutics vs skin grafts [00:24:35] Reimbursement and health economics [00:38:39] CUTISS’ partnering and exit options [00:47:54] Automation and artificial intelligence [00:56:32] Europe can show its strength in biotech [00:58:52] Daniela Marino answers quick-fire questions
NOW PLAYING
Daniela Marino, CUTISS 🇨🇭 | Tissue Engineering, Skin Grafts | E42 [Sponsored]
No transcript for this episode yet
Similar Episodes
May 14, 2026 ·360m
May 14, 2026 ·310m
May 14, 2026 ·205m
May 14, 2026 ·85m
May 14, 2026 ·282m